Pioneering Therapeutics Targeting Cellular Stress Pathways

Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.

Learn More

Our Approach

Ribon explores novel areas of disease biology and uses deep expertise in drug discovery to advance its pipeline.

Learn More

Our Targets

Our platform enables us to develop first-in-class therapeutics targeting a wide variety of enzymes that use NAD+ as substrate.

Learn More
Sep 4

Cambridge, MA

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor

Learn More
Join our team of experts.
Find Out More